Mineralocorticoid receptors are present in skeletal muscle and represent a potential therapeutic target

FASEB Journal

Volumn 29, Issue 11, 2015, Pages 4544-4554

  Chadwick, Jessica A ^a   Hauck, J Spencer ^a   Lowe, Jeovanna ^a   Shaw, Jeremiah J ^a   Guttridge, Denis C ^a   Gomez Sanchez, Celso E ^b   Gomez Sanchez, Elise P ^b   Rafael Fortney, Jill A ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Aldosterone; Gene expression microarray; Muscular dystrophy; Spironolactone; Steroid hormone receptors

Indexed keywords

ALDOSTERONE; EPLERENONE; MESSENGER RNA; MINERALOCORTICOID RECEPTOR; SPIRONOLACTONE; LISINOPRIL; MELANOCORTIN RECEPTOR; MUSCLE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; EC50; GENE EXPRESSION; HUMAN; HUMAN CELL; IC50; MOUSE; MUSCULAR DYSTROPHY; MYOBLAST; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUADRICEPS FEMORIS MUSCLE; SKELETAL MUSCLE; WILD TYPE; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; METABOLISM; MUSCULAR DISEASES; SKELETAL MUSCLE CELL;

ALDOSTERONE; ANIMALS; CELL LINE; HUMANS; LISINOPRIL; MICE; MUSCLE FIBERS, SKELETAL; MUSCLE PROTEINS; MUSCULAR DISEASES; RECEPTORS, MELANOCORTIN; SPIRONOLACTONE;

EID: 84948807801     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.15-276782     Document Type: Article

References (58)

1. Mendell, J. R., Shilling, C., Leslie, N. D., and Flanigan, K. M., al-Dahhak, R., Gastier-Foster, J., Kneile, K., and Dunn, D. M., Duval, B., Aoyagi, A., Hamil, C., Mahmoud, M., Roush, K., Bird, L., Rankin, C., Lilly, H., Street, N., Chandrasekar, R., and Weiss, R. B. (2012) Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann. Neurol. 71, 304-313
2. Emery, A. E. (2002) The muscular dystrophies. Lancet 359, 687-695
3. DeSilva, S., and Drachman, D. B., Mellits, D., and Kuncl, R. W. (1987) Prednisone treatment in Duchenne muscular dystrophy. Long-term benefit. Arch. Neurol. 44, 818-822
4. Bauer, R., Straub, V., Blain, A., Bushby, K., and MacGowan, G. A. (2009) Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient car-diomyopathy. Eur. J. Heart Fail. 11, 463-471
5. Lo Cascio, V., Kanis, J. A., and Beneton, M. N., Bertoldo, F., Adami, S., Poggi, G., and Zanolin, M. E. (1995) Acute effects of deflazacort and prednisone on rates of mineralization and bone formation. Calcif. Tissue Int. 56, 109-112
6. Angelini, C., and Peterle, E. (2012) Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy. Acta Myol. 31, 9-15
7. Rafael-Fortney, J. A., Chimanji, N. S., and Schill, K. E., Martin, C. D., Murray, J. D., Ganguly, R., and Stangland, J. E., Tran, T., Xu, Y., Canan, B. D., and Mays, T. A., Delfín, D. A., Janssen, P. M., and Raman, S. V. (2011) Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice. Circulation 124, 582-588
8. Zhou, L., Rafael-Fortney, J. A., Huang, P., Zhao, X. S., Cheng, G., Zhou, X., Kaminski, H. J., Liu, L., and Ransohoff, R. M. (2008) Haploinsufficiency of utrophin gene worsens skeletal muscle inflammation and fibrosis in mdx mice. J. Neurol. Sci. 264, 106-111
9. Messaoudi, S., Azibani, F., Delcayre, C., and Jaisser, F. (2012) Aldosterone, mineralocorticoid receptor, and heartfailure. Mol. Cell. Endocrinol. 350, 266-272
10. Chitnis, A. S., and Aparasu, R. R., Chen, H., and Johnson, M. L. (2012) Comparative effectiveness of different angiotensin-converting enzyme inhibitors on the risk of hospitalization in patients with heart failure. J. Comp. Eff. Res. 1, 195-206
11. Tamargo, J., Solini, A., and Ruilope, L. M. (2014) Comparison of agents that affect aldosterone action. Semin. Nephrol. 34, 285-306
12. Delyani, J. A., Rocha, R., Cook, C. S., Tobert, D.S., Levin, S., Roniker, B., Workman, D.L., Sing, Y.L., and Whelihan, B. (2001) Eplerenone: a selective aldosterone receptor antagonist (SARA). Cardiovasc. Drug Rev. 19, 185-200
13. Lowe, J., and Wodarcyk, A. J., Floyd, K. T., Rastogi, N., Schultz, E. J., Swager, S.A., Chadwick, J.A., Tran, T., Raman, S.V., Janssen, P.M.L., and Rafael-Fortney, J.A. (2015) The angiotensin converting enzyme inhibitor lisinopril improves muscle histopathology but not contractile function in a mouse model of Duchenne muscular dystrophy. J. Neuromusc. Dis. In press
14. Weinberger, C., Giguère, V., Hollenberg, S. M., Thompson, C., Arriza, J., and Evans, R.M. (1987) Humansteroid receptorsand erb-A gene products form a superfamily of enhancer-binding proteins. Clin. Physiol. Biochem. 5, 179-189
15. Arriza, J. L., Weinberger, C., Cerelli, G., Glaser, T. M., and Handelin, B. L., Housman, D. E., and Evans, R. M. (1987) Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237, 268-275
16. Evans, R. M. (1988) The steroid and thyroid hormone receptor superfamily. Science 240, 889-895
17. Yang, J., and Young, M.J. (2009) The mineralocorticoid receptor and its coregulators. J. Mol. Endocrinol. 43, 53-64
18. Hawkins, U. A., Gomez-Sanchez, E. P., Gomez-Sanchez, C. M., and Gomez-Sanchez, C. E. (2012) The ubiquitous mineralocorticoid receptor: clinical implications. Curr. Hypertens. Rep. 14, 573-580
19. Odermatt, A., and Kratschmar, D. V. (2012) Tissue-specific modulation of mineralocorticoid receptor functionby 11b-hydroxysteroid dehydrogenases: an overview. Mol. Cell. Endocrinol. 350, 168-186
20. Gomez-Sanchez, E. P., Gomez-Sanchez, M. T., de Rodriguez, A. F., Romero, D. G., Warden, M. P., Plonczynski, M. W., and Gomez-Sanchez, C. E. (2009) Immunohistochemical demonstration of the miner-alocorticoid receptor, 11beta-hydroxysteroid dehydrogenase-1 and -2, and hexose-6-phosphate dehydrogenase in rat ovary. J. Histochem. Cytochem. 57, 633-641
21. Gomez-Sanchez, E. P. (2004) Brain mineralocorticoid receptors: orchestrators of hypertension and end-organ disease. Curr. Opin. Nephrol. Hypertens. 13, 191-196
22. Gomez-Sanchez, C.E, Warden, M., Gomez-Sanchez, M. T., Hou, X., and Gomez-Sanchez, E. P. (2011) Diverse immunostaining patterns of mineralocorticoid receptor monoclonal antibodies. Steroids 76, 1541-1545
23. Viengchareun, S., Le Menuet, D., Martinerie, L., Munier, M., Pascual-Le Tallec, L., and Lombès, M. (2007) The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology. Nucl. Recept. Signal. 5, e012
24. Lastra, G., Whaley-Connell, A., Manrique, C., Habibi, J., Gutweiler, A. A., Appesh, L., and Hayden, M. R., Wei, Y., Ferrario, C., and Sowers, J. R. (2008) Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am. J. Physiol. Endocrinol. Metab. 295, E110-E116
25. Latouche, C., Sainte-Marie, Y., Steenman, M., Castro Chaves, P., Naray-Fejes-Toth, A., Fejes-Toth, G., Farman, N., and Jaisser, F. (2010) Molecular signature of mineralocorticoid receptor signaling in cardiomyocytes: from cultured cells to mouse heart. Endocrinology 151, 4467-4476
26. Jaisser, F., Farman, N., Sainte-Marie, Y., Latouche, C., Steenman, M. (2010) Biomarkers of mineralocorticoid receptor activation. U.S. Patent Application No. 20110257140
27. Bulfield, G., and Siller, W. G., Wight, P. A., and Moore, K. J. (1984) X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc. Natl. Acad. Sci. USA 81, 1189-1192
28. Sicinski, P., Geng, Y., Ryder-Cook, A. S., Barnard, E. A., Darlison, M. G., and Barnard, P. J. (1989) The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 244, 1578-1580
29. Deconinck, A. E., and Rafael, J. A., Skinner, J. A., Brown, S. C., and Potter, A. C., Metzinger, L., Watt, D. J., and Dickson, J. G., Tinsley, J. M., and Davies, K. E. (1997) Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 90, 717-727
30. Janssen, P. M., and Murray, J. D., Schill, K. E., Rastogi, N., Schultz, E. J., Tran, T., and Raman, S. V., and Rafael-Fortney, J.A. (2014) Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy. PLoS One 9, e88360
31. Gomez-Sanchez, C. E., de Rodriguez, A. F., Romero, D. G., Estess, J., Warden, M. P., Gomez-Sanchez, M. T., and Gomez-Sanchez, E. P. (2006) Development of a panel of monoclonal antibodies against the mineralocorticoid receptor. Endocrinology 147, 1343-1348
32. Clyne, C. D., and Chang, C. Y., Safi, R., Fuller, P. J., and McDonnell, D. P., and Young, M. J. (2009) Purification and characterization of recombinant human mineralocorticoid receptor. Mol. Cell. Endocrinol. 302, 81-85
33. Baker, P. E., and Kearney, J. A., Gong, B., Merriam, A. P., and Kuhn, D. E., Porter, J. D., and Rafael-Fortney, J. A. (2006) Analysis of gene expression differences between utrophin/dystrophin-deficient vs. mdx skeletal muscles reveals a specific upregulation of slow muscle genes in limb muscles. Neurogenetics 7, 81-91
34. Bakay, M., Zhao, P., Chen, J., and Hoffman, E. P. (2002) A Web-accessible complete transcriptome of normal human and DMD muscle. Neuromuscul. Disord. 12(Suppl 1), S125-S141
35. Ueda, K., Fujiki, K., Shirahige, K., Gomez-Sanchez, C. E., Fujita, T., Nangaku, M., and Nagase, M. (2014) Genome-wide analysis of mu-rine renal distal convoluted tubular cells for the target genes of mineralocorticoid receptor. Biochem. Biophys. Res. Commun. 445, 132-137
36. Kojic, S., Radojkovic, D., and Faulkner, G. (2011) Muscle ankyrin repeat proteins: their role in striated muscle function in health and disease. Crit. Rev. Clin. Lab. Sci. 48, 269-294
37. Zennaro, M. C., Souque, A., Viengchareun, S., Poisson, E., and Lombès, M. (2001) A new human MR splice variant is a ligand-independent transactivator modulating corticosteroid action. Mol. Endocrinol. 15, 1586-1598
38. Bledsoe, R. K., and Madauss, K. P., Holt, J. A., Apolito, C. J., and Lambert, M. H., Pearce, K. H., Stanley, T. B., and Stewart, E. L., Trump, R. P., Willson, T. M., and Williams, S. P. (2005) A ligand-mediated hydrogen bond network required for the activation of the mineralocorti-coid receptor. J. Biol. Chem. 280, 31283-31293
39. Rogerson, F. M., Yao, Y., Smith, B. J., and Fuller, P. J. (2004) Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor. Clin. Exp. Pharmacol. Physiol. 31, 704-709
40. Burniston, J. G., Saini, A., Tan, L. B., and Goldspink, D. F. (2005) Aldosterone induces myocyte apoptosis in the heart and skeletal muscles of rats in vivo. J. Mol. Cell. Cardiol. 39, 395-399
41. Young, M. J., and Rickard, A. J. (2012) Mechanisms of mineralocorticoid salt-induced hypertension and cardiac fibrosis. Mol. Cell. Endocrinol. 350, 248-255
42. El Haddad, M., Jean, E., Turki, A., Hugon, G., Vernus, B., Bonnieu, A., Passerieux, E., Hamade, A., Mercier, J., Laoudj-Chenivesse, D., and Carnac, G. (2012) Glutathione peroxidase 3, a new retinoid target gene, is crucial for human skeletal muscle precursor cell survival. J. Cell Sci. 125, 6147-6156
43. Rubin, H., and Wang, Z. M., Nickbarg, E. B., McLarney, S., Naidoo, N., and Schoenberger, O. L., Johnson, J. L., and Cooperman, B. S. (1990) Cloning, expression, purification, and biological activity of recombinant native and variant human alpha 1-antichymotrypsins. J. Biol. Chem. 265, 1199-1207
44. Caughey, G. H. (2011) Mast cell proteases as protective and inflammatory mediators. Adv. Exp. Med. Biol. 716, 212-234
45. Lannan, E. A., Galliher-Beckley, A. J., Scoltock, A. B., and Cidlowski, J. A. (2012) Proinflammatory actions of glucocorticoids: glucocorticoids and TNFa coregulate gene expression in vitro and in vivo. Endocrinology 153, 3701-3712
46. Anand-Srivastava, M. B. (2005) Natriuretic peptide receptor-C signaling and regulation. Peptides 26, 1044-1059
47. Lother, A., Moser, M., Bode, C., Feldman, R. D., and Hein, L. (2015) Mineralocorticoids in the heart and vasculature: new insights for old hormones. Annu. Rev. Pharmacol. Toxicol. 55, 289-312
48. Vasques, G. A., and Arnhold, I. J., and Jorge, A. A. (2014) Role of the natriuretic peptide system in normal growth and growth disorders. Horm. Res. Paediatr. 82, 222-229
49. Okazaki, K., and Sagata, N. (1995) The Mos/MAP kinase pathway stabilizes c-Fos by phosphorylation and augments its transforming activity in NIH 3T3 cells. EMBO J. 14, 5048-5059
50. Rincon Garriz, J. M., Suarez, C., and Capponi, A. M. (2009) c-Fos mediates angiotensin II-induced aldosterone production and protein synthesis in bovine adrenal glomerulosa cells. Endocrinology 150, 1294-1302
51. Takekawa, M., and Saito, H. (1998) A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK. Cell 95, 521-530
52. Kim, J. H., Qu, A., Reddy, J. K., Gao, B., and Gonzalez, F. J. (2014) Hepatic oxidative stress activates the Gadd45b gene by way of degradation of the transcriptional repressor STAT3. Hepatology 59, 695-704
53. Stewart, C. E., and Newcomb, P. V., and Holly, J. M. (2004) Multifaceted roles of TNF-alpha in myoblast destruction: a multitude of signal transduction pathways. J. Cell. Physiol. 198, 237-247
54. Laure, L., Suel, L., Roudaut, C., Bourg, N., Ouali, A., Bartoli, M., Richard, I., and Danièle, N. (2009) Cardiac ankyrin repeat protein is a marker of skeletal muscle pathological remodelling. FEBS J. 276, 669-684
55. Casey, W. M., Brodie, T., Yoon, L., Ni, H., and Jordan, H. L., and Cariello, N. F. (2008) Correlation analysis of gene expression and clinical chemistry to identify biomarkers of skeletal myopathy in mice treated with PPAR agonist GW610742X. Biomarkers 13, 364-376
56. Nakada, C., Tsukamoto, Y., Oka, A., Nonaka, I., Takeda, S., Sato, K., Mori, S., Ito, H., and Moriyama, M. (2003) Cardiac-restricted ankyrin-repeated protein is differentially induced in Duchenne and congenital muscular dystrophy. Lab. Invest. 83, 711-719
57. Duboc, D., Meune, C., Lerebours, G., Devaux, J. Y., Vaksmann, G., and Bécane, H. M. (2005) Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J. Am. Coll. Cardiol. 45, 855-857
58. Raman, S.V., Hor, K.N., Mazur, W., Halnon, N.J., Kissel, J.T., He, X., Tran, T., Smart, S., McCarthy, B., Taylor, M. D., and Jefferies, J. L., Rafael-Fortney, J. A., Lowe, J., Roble, S. L., and Cripe, L. H. (2015) Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 14, 153-161